These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23399727)

  • 1. Proposed mechanisms of action for prostate cancer vaccines.
    Geary SM; Lemke CD; Lubaroff DM; Salem AK
    Nat Rev Urol; 2013 Mar; 10(3):149-60. PubMed ID: 23399727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer vaccines: current status and future potential.
    Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
    BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.
    Plosker GL
    BioDrugs; 2011 Aug; 25(4):255-6. PubMed ID: 21815700
    [No Abstract]   [Full Text] [Related]  

  • 4. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
    Becze E
    ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750
    [No Abstract]   [Full Text] [Related]  

  • 6. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapies for castration-resistant prostate cancer.
    Longo DL
    N Engl J Med; 2010 Jul; 363(5):479-81. PubMed ID: 20818868
    [No Abstract]   [Full Text] [Related]  

  • 8. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.
    Graff JN; Drake CG; Beer TM
    Urology; 2013 Feb; 81(2):381-3. PubMed ID: 23374810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sipuleucel-T shows partial advantage in prostate cancer.
    Gould P
    Lancet Oncol; 2006 Sep; 7(9):710. PubMed ID: 16981300
    [No Abstract]   [Full Text] [Related]  

  • 12. Sipuleucel-T (APC8015) for prostate cancer.
    So-Rosillo R; Small EJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
    Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
    Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer immunology - an update for Urologists.
    Rajarubendra N; Lawrentschuk N; Bolton DM; Klotz L; Davis ID
    BJU Int; 2011 Apr; 107(7):1046-51. PubMed ID: 21070575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA-based vaccines for the treatment of prostate cancer.
    Madan RA; Gulley JL; Arlen PM
    Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Sartor O
    BJU Int; 2012 Jul; 110(2 Pt 2):E105. PubMed ID: 22176510
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccination therapy in prostate cancer.
    Marrari A; Iero M; Pilla L; Villa S; Salvioni R; Valdagni R; Parmiani G; Rivoltini L
    Cancer Immunol Immunother; 2007 Apr; 56(4):429-45. PubMed ID: 17031640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.